Investor Presentaiton
IV Appendix
Income Statement
In EGP
Gross Revenue
4Q2018
4Q2019
YOY▲
3,995,353
4,783,860
19.7%
FY2018
13,677,881
FY2019
16,941,029
YOY
23.9%
Net Revenue
3,890,288
4,671,104
20.1%
13,323,674
16,600,460
24.6%
Cost of Revenue
(3,573,779)
(4,276,757)
Gross Profit
Gross Profit Margin
316,509
8.14%
394,346
24.6%
8.44%
Selling, General & Administrative
(174,646)
(200,863)
(12,199,359)
1,124,315
8.44%
(569,491)
(15,161,005)
1,439,455
8.67%
(689,229)
28.0%
EBITDA
141,863
193,484
36.4%
554,824
750,226
35.2%
EBITDA Margin
3.65%
3.90%
4.16%
4.52%
Depreciation & Amortization
(3,314)
(27,795)
(41,421)
(86,229)
EBIT
EBIT Margin
Financial Expenses
Other Expenses
160,483
109,523
-31.8%
513,403
663,996
29.3%
3.56%
(39,476)
3.55%
3.85%
(89,225)
(25,198)
508
(125,843)
(59,360)
4.00%
(252,510)
(15,193)
Other Income
25,327
23,112
27,657
24,590
EBT
99,202
100,084
0.9%
355,856
420,883
18.3%
EBT Margin
2.55%
2.14%
2.67%
2.54%
Deferred Tax
(1,672)
(5,166)
(650)
344
Income Tax
(25,600)
(12,726)
(92,684)
(92,456)
Net Profit
71,930
82,193
14.3%
262,522
328,771
25.2%
Net Profit Margin
1,85%
1.76%
1.97%
1.98%
EPS
0.13
0.05
0.36
0.40
ibnsinapharma
Source: Company Management
(1) Gross revenue includes transportation revenue
32
32View entire presentation